Removal of Cellular-Type Hemoglobin-Based Oxygen Carrier (Hemoglobin-Vesicles) From Blood Using Centrifugation and Ultrafiltration

Hiromi Sakai, Keitaro Sou, Hirohisa Horinouchi, Eishun Tsuchida, Koichi Kobayashi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The hemoglobin-vesicle (HbV) is an artificial oxygen carrier encapsulating a concentrated hemoglobin solution in a phospholipid vesicle (liposome). During or after transporting oxygen, macrophages capture HbVs in the reticuloendothelial system (RES) with an approximate circulation half-life of 3 days. Animal studies show transient splenohepatomegaly after large doses, but HbVs were completely degraded, and the components were excreted in a few weeks. If a blood substitute is used for emergency use until red blood cell transfusion becomes available or for temporary use such as a priming fluid for an extracorporeal circuit, then one option would be to remove HbVs from the circulating blood without waiting a few weeks for removal by the RES. Using a mixture of beagle dog whole blood and HbV, we tested the separation of HbV using a centrifugal Fresenius cell separator and an ultrafiltration system. The cell separator system separated the layers of blood cell components from the HbV-containing plasma layer by centrifugal force, and then the HbV was removed from plasma phase by the ultrafiltration system. The HbVs (250-280nm) are larger than plasma proteins (<22nm diameter) but smaller than blood cell components (>3μm). The size of HbVs is advantageous to be separated from the original blood components, and the separated blood components can be returned to circulation.

Original languageEnglish
Pages (from-to)202-209
Number of pages8
JournalArtificial Organs
Volume36
Issue number2
DOIs
Publication statusPublished - 2012 Feb

Fingerprint

Centrifugation
Hemoglobin
Ultrafiltration
Hemoglobins
Blood
Oxygen
Mononuclear Phagocyte System
Separators
Plasmas
Blood substitutes
Cells
Blood Substitutes
Erythrocyte Transfusion
Liposomes
Macrophages
Phospholipids
Cellular Structures
Half-Life
Blood Proteins
Blood Cells

Keywords

  • Blood purification
  • Blood substitute
  • Cardiopulmonary bypass
  • Centrifugation
  • Hemoglobin-vesicles
  • Oxygen carrier
  • Separation

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Removal of Cellular-Type Hemoglobin-Based Oxygen Carrier (Hemoglobin-Vesicles) From Blood Using Centrifugation and Ultrafiltration. / Sakai, Hiromi; Sou, Keitaro; Horinouchi, Hirohisa; Tsuchida, Eishun; Kobayashi, Koichi.

In: Artificial Organs, Vol. 36, No. 2, 02.2012, p. 202-209.

Research output: Contribution to journalArticle

Sakai, Hiromi ; Sou, Keitaro ; Horinouchi, Hirohisa ; Tsuchida, Eishun ; Kobayashi, Koichi. / Removal of Cellular-Type Hemoglobin-Based Oxygen Carrier (Hemoglobin-Vesicles) From Blood Using Centrifugation and Ultrafiltration. In: Artificial Organs. 2012 ; Vol. 36, No. 2. pp. 202-209.
@article{fb50268a7959498499f3c56cecccd6c8,
title = "Removal of Cellular-Type Hemoglobin-Based Oxygen Carrier (Hemoglobin-Vesicles) From Blood Using Centrifugation and Ultrafiltration",
abstract = "The hemoglobin-vesicle (HbV) is an artificial oxygen carrier encapsulating a concentrated hemoglobin solution in a phospholipid vesicle (liposome). During or after transporting oxygen, macrophages capture HbVs in the reticuloendothelial system (RES) with an approximate circulation half-life of 3 days. Animal studies show transient splenohepatomegaly after large doses, but HbVs were completely degraded, and the components were excreted in a few weeks. If a blood substitute is used for emergency use until red blood cell transfusion becomes available or for temporary use such as a priming fluid for an extracorporeal circuit, then one option would be to remove HbVs from the circulating blood without waiting a few weeks for removal by the RES. Using a mixture of beagle dog whole blood and HbV, we tested the separation of HbV using a centrifugal Fresenius cell separator and an ultrafiltration system. The cell separator system separated the layers of blood cell components from the HbV-containing plasma layer by centrifugal force, and then the HbV was removed from plasma phase by the ultrafiltration system. The HbVs (250-280nm) are larger than plasma proteins (<22nm diameter) but smaller than blood cell components (>3μm). The size of HbVs is advantageous to be separated from the original blood components, and the separated blood components can be returned to circulation.",
keywords = "Blood purification, Blood substitute, Cardiopulmonary bypass, Centrifugation, Hemoglobin-vesicles, Oxygen carrier, Separation",
author = "Hiromi Sakai and Keitaro Sou and Hirohisa Horinouchi and Eishun Tsuchida and Koichi Kobayashi",
year = "2012",
month = "2",
doi = "10.1111/j.1525-1594.2011.01236.x",
language = "English",
volume = "36",
pages = "202--209",
journal = "Artificial Organs",
issn = "0160-564X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Removal of Cellular-Type Hemoglobin-Based Oxygen Carrier (Hemoglobin-Vesicles) From Blood Using Centrifugation and Ultrafiltration

AU - Sakai, Hiromi

AU - Sou, Keitaro

AU - Horinouchi, Hirohisa

AU - Tsuchida, Eishun

AU - Kobayashi, Koichi

PY - 2012/2

Y1 - 2012/2

N2 - The hemoglobin-vesicle (HbV) is an artificial oxygen carrier encapsulating a concentrated hemoglobin solution in a phospholipid vesicle (liposome). During or after transporting oxygen, macrophages capture HbVs in the reticuloendothelial system (RES) with an approximate circulation half-life of 3 days. Animal studies show transient splenohepatomegaly after large doses, but HbVs were completely degraded, and the components were excreted in a few weeks. If a blood substitute is used for emergency use until red blood cell transfusion becomes available or for temporary use such as a priming fluid for an extracorporeal circuit, then one option would be to remove HbVs from the circulating blood without waiting a few weeks for removal by the RES. Using a mixture of beagle dog whole blood and HbV, we tested the separation of HbV using a centrifugal Fresenius cell separator and an ultrafiltration system. The cell separator system separated the layers of blood cell components from the HbV-containing plasma layer by centrifugal force, and then the HbV was removed from plasma phase by the ultrafiltration system. The HbVs (250-280nm) are larger than plasma proteins (<22nm diameter) but smaller than blood cell components (>3μm). The size of HbVs is advantageous to be separated from the original blood components, and the separated blood components can be returned to circulation.

AB - The hemoglobin-vesicle (HbV) is an artificial oxygen carrier encapsulating a concentrated hemoglobin solution in a phospholipid vesicle (liposome). During or after transporting oxygen, macrophages capture HbVs in the reticuloendothelial system (RES) with an approximate circulation half-life of 3 days. Animal studies show transient splenohepatomegaly after large doses, but HbVs were completely degraded, and the components were excreted in a few weeks. If a blood substitute is used for emergency use until red blood cell transfusion becomes available or for temporary use such as a priming fluid for an extracorporeal circuit, then one option would be to remove HbVs from the circulating blood without waiting a few weeks for removal by the RES. Using a mixture of beagle dog whole blood and HbV, we tested the separation of HbV using a centrifugal Fresenius cell separator and an ultrafiltration system. The cell separator system separated the layers of blood cell components from the HbV-containing plasma layer by centrifugal force, and then the HbV was removed from plasma phase by the ultrafiltration system. The HbVs (250-280nm) are larger than plasma proteins (<22nm diameter) but smaller than blood cell components (>3μm). The size of HbVs is advantageous to be separated from the original blood components, and the separated blood components can be returned to circulation.

KW - Blood purification

KW - Blood substitute

KW - Cardiopulmonary bypass

KW - Centrifugation

KW - Hemoglobin-vesicles

KW - Oxygen carrier

KW - Separation

UR - http://www.scopus.com/inward/record.url?scp=84857066851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857066851&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1594.2011.01236.x

DO - 10.1111/j.1525-1594.2011.01236.x

M3 - Article

VL - 36

SP - 202

EP - 209

JO - Artificial Organs

JF - Artificial Organs

SN - 0160-564X

IS - 2

ER -